Memphis, TNNCT07226219Now EnrollingIRB Ready

Sickle Cell Disease Clinical Trial in Memphis, TN

Access cutting-edge sickle cell disease treatment through this phase 1 clinical trial at a research site in Memphis. Study-provided care at no cost to qualified participants.

Sponsored by St. Jude Children's Research Hospital

Quick Self-Assessment

See if you qualify for this Memphis location

Preparing your pre-screening questions…

Expert Care in Memphis

Access sickle cell disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sickle cell disease treatment provided free

Apply for This Memphis Location

Check if you qualify for this sickle cell disease clinical trial in Memphis, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Memphis

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Memphis site if eligible
  4. 4Begin participation

About This Sickle Cell Disease Study in Memphis

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Sponsor: St. Jude Children's Research Hospital

Who Can Participate

Inclusion Criteria

Diagnosed with SCD of any genotype
Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP)
Between the ages of 8.0 and 17.9 years \*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):
\*Score at or below the 16th percentile on any 2 out of 4 performance measures:
NIH Toolbox Flanker
NIH Toolbox List Sorting
NIH Toolbox Dimensional Change Card Sort Test (DCST)
Wechsler Intelligence Scale for Children (WISC) -5/ Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF)
\*Score at or above the 84th percentile on any 1 out of 2 parent rating scales:
BRIEF-2 Global Executive
BASC-3 Attention
\*Have a documented diagnosis of attention deficit / hyperactivity disorder (any subtype)
English as the primary language
Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines
Negative pregnancy test

Exclusion Criteria

Primary language other than English
Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test
Uncontrolled seizures (seizure within the past 6 months)
Cardiomyopathy or known congenital structural cardiac defects
Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis
History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, QT prolongation or concomitant use of medications associated with QT prolongation
Two or more prior episodes of priapism
Blood pressure \>95th percentile at the three most recent visits consecutively (i.e., \>95th percentile reading at all three of the most recent hospital visits to St. Jude).
If blood pressure is \> 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings.
Stimulant medication within the past two weeks
Severe sensory loss
Previous adverse reaction to methylphenidate
Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Currently prescribed another investigational medication.
Currently prescribed any of the following:
Phenobarbital (anticonvulsant)
Phenytoin (anticonvulsant)
Primidone (anticonvulsant)
Warfarin (anticoagulant)
Antipsychotic medications
Selective Serotonin Reuptake Inhibitor (SSRI) medications
Tricyclic antidepressant (TCA) medications
Vasopressor medications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT07226219) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sickle Cell Disease Treatment Options in Memphis, TN

If you're searching for sickle cell disease treatment options in Memphis, TN, this clinical trial (NCT07226219) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sickle cell disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Memphis, TN

See all ankylosing spondylitis clinical trials recruiting in Memphis — not just this study.

Browse Ankylosing Spondylitis Trials in Memphis →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsSickle Cell Disease TrialsAll Conditions →

Ready to Join in Memphis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Memphis, TN